ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sagimet Biosciences Receives Fast Track Designation from FDA for NASH Treatment
March 24, 2021Sagimet Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH. -
Sagimet Announces Positive Results in NASH Trial of FASN Inhibitor TVB-2640
June 29, 2020Sagimet Biosciences announced positive results from FASCINATE-1, the Phase 2 clinical trial of its oral, once-daily FASN inhibitor TVB-2640, the company's lead product candidate that is currently being evaluated as a potential treatment for ...
Pharma Sources Insight January 2025
